Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for residual limb pain after major lower limb amputation
ACTRN12626001192370Phase 3Not yet recruiting
- Sponsor
- Auckland University of Technology
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in Residual limb pain (RLP) (2 arms), sponsored by Auckland University of Technology. Primary endpoint: Proportion of responders with at least 50% improvement in residual limb pain. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Residual limb pain (RLP)
Beyond the preview
Go deeper on ACTRN12626001192370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001192370.